Bristol-Myers Squibb Company (NYSE: BMY) reported third-quarter 2020 financial results before the market opened on Thursday. The pharmaceutical company reported a 75% growth in Q3 revenue of $10.5 billion, surpassing the Wall Street consensus. The company reported a net income of $1.63 per share, better than what analysts had anticipated.
BMY shares gained 1.8% immediately following the announcement. The stock has traded mostly flattish so far this year.
Last month, the company had announced the acquisition of MyoKardia Inc. for $13.1 billion in cash. The deal, which amounts to $225 per share, was approved by the Boards of Directors of both companies and is expected to close during the fourth quarter of 2020.
This transaction will give Bristol Myers access to the medicine mavacamten intended for the treatment of the chronic heart disease obstructive hypertrophic cardiomyopathy (HCM), thus helping in expanding its cardiovascular portfolio.
Mavacamten has the potential to become a significant medium and long-term growth driver due to the vast unmet medical need in obstructive HCM. The deal is expected to be slightly dilutive to Bristol’s adjusted EPS in 2021 and 2022 and become accretive from 2023.
Prior performance
Most Popular
Infographic: How Lennar (LEN) performed in Q4 2025
Lennar Corporation (NYSE: LEN) reported total revenues of $9.4 billion for the fourth quarter of 2025, compared to $9.9 billion reported in the same period a year ago. Net earnings
Paychex expected to report higher revenue and earnings for Q2 FY26
Paychex, Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is undergoing an AI-driven transformation that enhances both its internal operations and client-facing services. Entering fiscal 2026, the
Signet Jewelers (SIG): A look at the progress made on Grow Brand Love
Shares of Signet Jewelers Limited (NYSE: SIG) fell over 3% on Tuesday. The stock has gained 3% year-to-date. The jewelry retailer delivered strong results for the third quarter of 2026,
Comments